The FDA has approved a GSK medicine that might change how doctors treat some rectal cancers.

Oct 19, 2026, 2:14 PM ETTrialRead the original at Benzinga

Good for GSK

FDA approval gives GSK's Jemperli a new use, and nearly 75% of 154 trial patients avoided surgery, chemotherapy, and radiation. The group covers only 3% to 10% of rectal cancer patients, and complete-response results ranged from 47% to 68%, but approval still expands the drug's use.

GSK · GSK plc

AI read · Good for GSK

The AI's read

Nearly 75% of patients in the study avoided surgery, chemotherapy, and radiation, giving GSK a chance to use Jemperli with a new patient group. The group is small, and complete-response results were 68% in investigator assessments versus 47% in independent reviews. The approval still creates a new use, though the full trial results are due in October 2026.

Get alerts for GSK

Follow GSK plc (GSK) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GSK

Free on the App Store and Google Play, or on the web.